Patents Assigned to Jazz Pharmaceuticals, Inc.
-
Patent number: 11456081Abstract: A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients and/or caregivers. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.Type: GrantFiled: July 11, 2018Date of Patent: September 27, 2022Assignee: Jazz Pharmaceuticals, Inc.Inventors: Prasheel Vashdev Lillaney, Sherice ReneƩ Mills, Gary Joseph Appio
-
Patent number: 11410779Abstract: A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients and/or caregivers. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.Type: GrantFiled: July 11, 2018Date of Patent: August 9, 2022Assignee: Jazz Pharmaceuticals, Inc.Inventors: Prasheel Vashdev Lillaney, Sherice ReneƩ Mills, Gary Joseph Appio
-
Patent number: 11207270Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.Type: GrantFiled: July 20, 2021Date of Patent: December 28, 2021Assignee: JAZZ PHARMACEUTICALS, INC.Inventors: Clark Allphin, James Pfeiffer
-
Patent number: 11090269Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.Type: GrantFiled: April 7, 2021Date of Patent: August 17, 2021Assignee: JAZZ PHARMACEUTICALS, INC.Inventors: Clark Allphin, James Pfeiffer
-
Patent number: 11033530Abstract: A device includes a reservoir configured to store a drug formulation including at least one abuse-preventing additive. The device further includes means configured to remove the at least one abuse-preventing additive. The device further includes means configured to prevent access to the drug formulation.Type: GrantFiled: September 25, 2017Date of Patent: June 15, 2021Assignee: JAZZ PHARMACEUTICALS, INC.Inventor: Clark Allphin
-
Patent number: 10987310Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.Type: GrantFiled: December 12, 2019Date of Patent: April 27, 2021Assignee: JAZZ PHARMACEUTICALS, INC.Inventors: Clark Allphin, James Pfeiffer
-
Patent number: 10966931Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.Type: GrantFiled: September 4, 2020Date of Patent: April 6, 2021Assignee: JAZZ PHARMACEUTICALS, INC.Inventors: Clark Allphin, James Pfeiffer
-
Patent number: 10959956Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.Type: GrantFiled: September 4, 2020Date of Patent: March 30, 2021Assignee: JAZZ PHARMACEUTICALS, INC.Inventors: Clark Allphin, James Pfeiffer
-
Patent number: 10813885Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.Type: GrantFiled: June 30, 2020Date of Patent: October 27, 2020Assignee: JAZZ PHARMACEUTICALS, INC.Inventors: Clark Allphin, James Pfeiffer
-
Patent number: 10758488Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.Type: GrantFiled: July 2, 2018Date of Patent: September 1, 2020Assignee: JAZZ PHARMACEUTICALS, INC.Inventors: Clark Allphin, James Pfeiffer
-
Patent number: 9801852Abstract: A method for providing a drug includes providing an inactive form of a drug. The method also includes chemically converting the inactive form of the drug to an active form to provide a drug formulation usable by a patient in need thereof, including using a device configured to remove an abuse-preventing additive from the inactive form of the drug. The method also includes dispensing the drug formulation to the patient in need thereof.Type: GrantFiled: September 2, 2014Date of Patent: October 31, 2017Assignee: JAZZ PHARMACEUTICALS, INC.Inventor: Clark Allphin
-
Patent number: 9795567Abstract: The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form.Type: GrantFiled: June 3, 2014Date of Patent: October 24, 2017Assignee: JAZZ PHARMACEUTICALS, INC.Inventors: Andrea Marie Rourke, Maura Patricia Murphy, James Frederick Pfeiffer, Clark Patrick Allphin, Alya Kahn McGinlay
-
Patent number: 9539330Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.Type: GrantFiled: November 9, 2015Date of Patent: January 10, 2017Assignee: Jazz Pharmaceuticals, Inc.Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
-
Publication number: 20150073052Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.Type: ApplicationFiled: April 10, 2014Publication date: March 12, 2015Applicant: Jazz Pharmaceuticals, Inc.Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
-
Patent number: 8952062Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.Type: GrantFiled: March 6, 2013Date of Patent: February 10, 2015Assignee: Jazz Pharmaceuticals, Inc.Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
-
Publication number: 20140348917Abstract: The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form.Type: ApplicationFiled: June 3, 2014Publication date: November 27, 2014Applicant: Jazz Pharmaceuticals, Inc.Inventors: Andrea Marie Rourke, Maura Patricia Murphy, James Frederick Pfeiffer, Clark Patrick Allphin, Alya Kahn McGinlay
-
Patent number: 8859619Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.Type: GrantFiled: November 26, 2012Date of Patent: October 14, 2014Assignee: Jazz Pharmaceuticals, Inc.Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
-
Publication number: 20140296830Abstract: One embodiment of the present invention is a method for reducing pain using a multi chamber pump to separately administer multiple drugs. For example, one chamber may contain an omega conopeptide, such as ziconotide, and the other chamber or chambers may contain one or more other drugs, which may include of morphine, hydromorphone, fentanyl, sufentanil, bupivacaine, baclofen, clonidine, and buprenorphine, or their pharmaceutically acceptable salts thereof. Other applications of the present invention include methods for treating severe chronic pain due to cancer, failed back syndrome, CRPS, neuropathic pain, mixed neuropathic and nociceptive pain.Type: ApplicationFiled: March 27, 2014Publication date: October 2, 2014Applicant: Jazz Pharmaceuticals, Inc.Inventors: Susan P. Gibson, Geertrui F. Vanhove
-
Publication number: 20140249222Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: ApplicationFiled: April 29, 2013Publication date: September 4, 2014Applicant: Jazz Pharmaceuticals, Inc.Inventor: Mark Eller
-
Publication number: 20140249115Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: ApplicationFiled: March 15, 2013Publication date: September 4, 2014Applicant: Jazz Pharmaceuticals, Inc.Inventor: Jazz Pharmaceuticals, Inc.